Tekion Launches AI Agents on Its Platform, Boosting Business Value for Automotive Retail
PLEASANTON, Calif., March 18, 2025--(BUSINESS WIRE)--Tekion, innovator of the first cloud-native platform serving the entire automotive retail ecosystem, announced today the next evolution of its AI-powered platform with the introduction of Tekion AI Agents. Building on the success of Tekion AI Copilot for Service, first unveiled at NADA 2025, Tekion plans to launch a first-of-its-kind suite of AI Agents for the automotive industry, starting with Tekion AI Agent for Service.
Tekion AI Agents represent the next evolution of AI within Tekion's Automotive Retail Cloud (ARC) platform, designed to move beyond assistance into full workflow automation. It functions as an autonomous AI solution that executes tasks and actions on behalf of users and organizations. AI Copilot streamlined communication between technicians, service advisors, and customers which was a great first step for AI adoption. Tekion AI Agents take action—handling complex service processes end-to-end with minimal manual input. Tekion AI Agent for Service is the first in a broader suite of AI-driven solutions, automating key workflows such as identifying necessary repairs, initiating approvals, and coordinating next steps, all while ensuring the right level of oversight.
"AI is at the core of Tekion's vision to modernize and transform automotive retail," said Jay Vijayan, Founder & CEO of Tekion. "Tekion AI is a Machine Learning Model (ML)-agnostic, Large Language Model (LLM)-agnostic, and vendor-agnostic AI engine that seamlessly integrates both Generative and Predictive AI models. This flexibility allows a seamless switch between models, ensuring the best results for our customers. Tekion AI is backed by a business context-rich, unified Data Layer that enables seamless adaptation to the rapidly evolving AI landscape. With Tekion AI Agents, we're moving beyond insights to real action—automating workflows, enhancing efficiency, and empowering dealership teams to deliver an unparalleled customer experience. Dealers are seeing real value, and this is just the beginning of what Tekion AI will bring to the industry."
Customer feedback:
"Tekion AI is revolutionizing our service department by allowing our advisors to focus more on customers and less on manual processes," said Finley Ewing IV, CEO of Ewing Automotive Group, one of the early adopters of Tekion AI. "Seeing AI recognize deferred recommendations, track mileage since the last service and proactively surface insights is beyond impressive. This level of automation not only helps technicians and advisors sell valuable services – it ultimately leads to safer cars on the road. We're excited for what's next with Tekion AI Agents, taking automation even further to enhance both the customer and dealership experience."
How Tekion AI Agent for Service Transforms Dealerships:
Seamless Task Execution – Automates end-to-end workflows, reducing manual intervention.
Enhanced Customer Interactions – Provides real-time, AI-driven service updates and approvals.
Increased Efficiency – Cuts down on administrative tasks, allowing advisors to spend more time with customers.
Improved Profitability – Reduces bottlenecks, enhances upsell opportunities, and drives operational success.
Tekion AI: A Vertical AI Solution for Automotive
Tekion AI Agents are part of Tekion AI, a broader Vertical AI initiative designed to revolutionize automotive retail operations across all departments. Unlike traditional AI tools focused on siloed tasks, Tekion AI Agents proactively execute dealership workflows end-to-end, ensuring real-time collaboration and process automation. The introduction of AI Agent for Service is just the beginning of many more to come.
About Tekion
Positively disrupting an industry that has not seen disruption in over 50 years, Tekion has challenged the paradigm with the first and fastest cloud-native automotive platform that includes the revolutionary Automotive Retail Cloud (ARC) for retailers, Automotive Enterprise Cloud (AEC) for manufacturers and other large automotive enterprises and Automotive Partner Cloud (APC) for technology and industry partners. Tekion connects the entire spectrum of the automotive retail ecosystem through one seamless platform. The transformative platform uses cutting-edge technology, big data, machine learning, and AI to seamlessly bring together OEMs, retailers/dealers and consumers. With its highly configurable integration and greater customer engagement capabilities, Tekion is enabling the best automotive retail experiences ever. For more information, visit www.tekion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318084635/en/
Contacts
Media Contact, Tekion: Marylou Hastert press@tekion.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Business Wire
a day ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
2 days ago
- Yahoo
Cameco Reports Expected Increase in Its Share of Westinghouse 2025 Adjusted EBITDA
All amounts in Canadian dollars unless specified otherwise SASKATOON, Saskatchewan, June 06, 2025--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) reports an expected increase of approximately $170 million (US) in our 49% equity share of Westinghouse Electric Company's (Westinghouse) 2025 second quarter and annual adjusted EBITDA. The expected increase is tied to Westinghouse's participation in the construction project for two nuclear reactors at the Dukovany power plant in the Czech Republic. This expected increase will be taken into consideration in determining the 2025 distribution payable by Westinghouse to Cameco. In addition to the increase in adjusted EBITDA in 2025, we expect significant financial benefits for Westinghouse, as a subcontractor, over the term of the Dukovany construction project and related to the provision of the fuel fabrication services required for both reactors for a specified period. The outlook for Westinghouse's compound annual growth rate for adjusted EBITDA remains 6% to 10% over the next five years, excluding the impact of the expected $170 million (US) increase in its 2025 adjusted EBITDA. Cameco owns a 49% interest in Westinghouse and its partner, Brookfield Renewable Partners, owns the remaining 51%. Caution about forward-looking informationThis news release includes statements and information about our expectations for the future, which we refer to as forward-looking information. Forward-looking information is based on our current views, which can change significantly, and actual results and events may be significantly different from what we currently expect. Examples of forward-looking information in this news release include our expectations regarding: Westinghouse's participation in the Dukovany power plant construction project; an increase in Westinghouse's adjusted EBITDA; Westinghouse taking this increase into consideration in determining the 2025 distribution payable to Cameco; the financial benefits for Westinghouse, as subcontractor, over the term of the Dukovany construction project and the expected future growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Material risks that could lead to different results include the risk that Westinghouse is not able to participate in the Dukovany construction project on a basis that achieves the currently expected benefits to Westinghouse for any reason, or that Cameco may not derive the expected increases in its share of Westinghouse's adjusted EBITDA, or that Westinghouse does not achieve the expected future annual growth in adjusted EBITDA. In presenting the forward-looking information, we have made material assumptions which may prove incorrect about Westinghouse's participation in the Dukovany construction project and related potential benefits to Westinghouse, and continuing growth in Westinghouse's compound annual growth rate for adjusted EBITDA. Non-IFRS MeasuresAdjusted EBITDA is a measure that does not have a standardized meaning or a consistent basis of calculation under International Financial Reporting Standards (a non-IFRS measure). Westinghouse's adjusted EBITDA is defined as its net income, adjusted for the impact of certain expenses, costs, charges or benefits incurred in such period which are either not indicative of underlying business performance or that impact the ability to assess the operating performance of its business. For more information regarding our use of this non-IFRS measure see our most recent annual and quarterly Management's Discussion and Analysis. ProfileCameco is one of the largest global providers of the uranium fuel needed to power a secure energy future. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations, as well as significant investments across the nuclear fuel cycle, including ownership interests in Westinghouse Electric Company and Global Laser Enrichment. Utilities around the world rely on Cameco to provide global nuclear fuel solutions for the generation of safe, reliable, carbon-free nuclear power. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan, Canada. As used in this news release, the terms we, us, our, the Company and Cameco mean Cameco Corporation and its subsidiaries unless otherwise indicated. View source version on Contacts Investor inquiries Cory Kos 306-716-6782 cory_kos@ Media inquiries Veronica Baker 306-385-5541 veronica_baker@ Sign in to access your portfolio
